Index of Contributors

Adams, J. C., 563–565
Adrian, T. E., 495–506, 566–567, 571–572
Aghajanian, G. K., 188–197
Agnati, L. F., 231–254, 315–333
Ambrose, F. G., 573–574
Andersson, K., 231–254
Andriès, J. C., 167–187
Arluson, M., 568–570
Autry, W. L., 573–574

Baali-Cherif, H., 568–570
Bacarese-Hamilton, A. J., 566–567, 571–572
Baile, C. A., 424–430
Barbaz, B. S., 573–574
Barone, P., 553–561
Bartness, T. J., 413–416
Battistini, N., 315–333
Beauvillain, J. C., 167–187
Bégué, D., 61–75, 598–600
Beinfeld, M. C., 44–52, 152–156, 403–412
Belemtougri, G., 167–187
Belleney, J., 61–75, 598–600
Benfenati, F., 315–333
Björklund, A., 488–494
Blanc, G., 306–314
Bloom, D., 535–541
Bloom, S. R., 495–506, 566–567, 571–572
Bradwejn, J., 575–580
Broekkamp, C. L. E., 604–606
Brooks, P. A., 361–374
Brownstein, M. J., 9–10, 255–274
Brundin, P., 488–494
Bruno, G., 553–561
Bunney, B. S., 345–351

Calza, L., 315–333
Carstens, E., 660–662
Champagnat, J., 375–384
Chase, T. N., 553–561, 663–664
Chiodo, L. A., 345–351
Ciarleglio, A., 44–52
Clark, C. R., 581–582
Coghill, R., 676–677
Cohen, S. L., 553–561
Conrath-Verrier, M., 583–585
Coons, E. E., 633–635
Crawley, J. N., 1–8, 283–292, 542–552, 586–588
Crow, T. J., 495–506
Csonka, C., 624–626
Culhane, E. S., 660–662

Daugé, V., 61–75
Daum, P., 581–582
Davison, J. S., 648–650
Dawbarn, D., 488–494
Della-Fera, M. A., 424–430
de Belleroche, J., 642–647
Debonnel, G., 535–541
Demeulemeester, H., 589–592
de Montigny, C., 575–580
Denavit-Saubié, M., 375–384
Deschenes, R. J., 53–60
Deschepper, C., 334–344
Deschodt-Lanckman, M., 87–98
Desmond, H., 32–43
de Wied, D., 671–673
De Witte, P., 470–487
Dhainaut-Courtois, N., 167–187
Dietl, M., 583–585
Dixon, J. E., 53–60
Dockray, G. J., 32–43, 255–274
Durieux, C., 61–75, 593–595, 598–600

Emson, P. C., 488–494
Eneroth, P., 231–254
Etienne, P., 624–626
Everitt, B., 255–274

Faden, A., 255–274
Fallon, J. H., 121–132, 596–597, 636–639
Faris, P. L., 437–447
Farmery, S. M., 495–506
Feldman, S. M., 633–635
Fellion, E., 61–75
Ferrier, I. N., 495–506
Fournié-Zaluski, M-C., 61–75, 593–595, 598–600
Foutz, A. S., 375–384
Frankfurt, M., 651–653
Freeman, A. S., 345–351
Frenk, H., 676–677
Frerot, O., 110–120
Frey, P., 601–603
Fuxe, K., 231–254, 315–353

Gacel, G., 61–75, 593–595, 598–600
Gaudreau, P., 198–219, 624–626
Gayton, R. J., 32–43
Gérard, D., 61–75, 598–600
Gerber, R., 573–574
Gewiss, M., 470–487
Giardino, L., 315–333
Gibbs, J., 417–423

Gilles, C., 507–517
Glowinski, J., 306–314
Goldfine, I. D., 220–230
Goldman, S., 334–344, 470–487
Goldstein, M., 231–254, 255–274, 315–333
Goltermann, N. R., 76–86
Gower, A. J., 604–606
Guidolin, D., 315–333

Hansen, H. F., 11–23
Härfstrand, A., 231–254
Haun, R. S., 53–60
Hays, S. E., 403–412
Hökfelt, T., 255–274, 403–412
Hommer, D. W., 275–282, 542–552
Hughes, J. J., 413–416, 581–582, 640–641
Hurlé, M. A., 375–384
Hutchison, J. B., 607–608

Innis, R. B., 188–197
Isacson, O., 488–494
Itoh, Koichi, 518–534
Itoh, Kozo, 518–534
Itoh, S., 616–620

Jacobs, T., 255–274
Jansen, J. B. M. J., 24–31
Javoy-Agid, F., 656–659
Jonsson, A-C., 32–43
Juncos, J., 553–561
Jurna, I., 609–612

Kádár, T., 293–305
Kaplan, J. M., 633–635
Kato, K., 613–615
Katsuura, G., 616–620
Kaufman, E., 676–677
Kelly, J. S., 361–374
Kenny, A. J., 666–668
Kinscheck, I. B., 676–677
Kiss, J. Z., 144–151, 152–156, 586–588
Knight, M., 553–561
Koob, G. F., 669–670
Kovács, G. L., 293–305
Kovács, K., 293–305
Kuga, S., 255–274

Lal, S., 535–541
Lamers, C. B. H. W., 24–31
Levine, A. S., 413–416, 640–641
Liebman, J. M., 573–574
Lotstra, F., 334–344, 507–517
Lucignani, G., 663–665
Lux, B., 61–75, 598–600

Malécha, J., 167–187
Marcel, R., 167–187
Markstein, R., 255–274
Marley, P. D., 11–23
Masson, M., 167–187
Matsas, R., 666–668
Matsubara, K., 613–615
Mayer, D. J., 676–677
McHugh, P. R., 621–623, 627–629
Meister, B., 255–274
Menant, I., 61–75, 598–600
Mendlewicz, J., 507–517
Meyer, D. K., 133–143
Mezey, E., 152–156
Miller, J., 676–677
Moran, T. H., 621–623, 627–629
Morgat, J. L., 61–75
Morin-Surun, M. P., 375–384
Morley, J. E., 413–416, 640–641
Moroji, T., 518–534
Mosticyan, S., 535–541
Mugnaini, E., 563–565
Murase, K., 385–402
Murphy, R. B., 633–635
Mutt, V., 231–254

Nahorski, S. R., 607–608
Nair, N. P. V., 535–541, 624–626
Nizielski, S. E., 413–416

Orban, G. A., 589–592
Osborne, N. N., 157–166
Owen, F., 495–506

Pahnke, U., 651–653
Panerai, A., 630–632
Paul, S. M., 542–552
Pélaprat, D., 61–75, 593–595
Penke, B., 293–305
Pert, C. B., 198–219
Petrack, B., 678–681
Pickar, D., 542–552
Porrino, L. J., 663–665
Protopapas, Z., 133–143

Quirion, R., 198–219, 624–626

Randić, M., 385–402
Raybould, H., 32–43
Rehfeld, J. F., 9–10, 11–23, 255–274, 488–494
Reibaud, M., 306–314
Reisine, T. D., 152–156
Roberts, G. W., 495–506
Robinson, P. H., 621–623, 627–629
Robitaille, Y., 624–626
Rogawski, M. A., 403–412
Roos, B. A., 53–60

Roques, B. P., 61–75, 470–487, 593–595, 598–600
Rose, C., 110–120, 685–686
Rosenquist, G., 676–677
Rossier, J., 334–344
Rossignol, P., 61–75
Rossor, M. N., 488–494
Rovati, L. C., 630–632
Ruggeri, M., 315–333
Ruggeri, S., 553–561
Ruiz-Gayo, M., 61–75

Sacerdote, P., 630–632
Sakamoto, C., 220–230
Sasaki, A., 61–75
Schiffmann, S., 334–344
Schneider, L. H., 633–635
Schultzberg, M., 99–109
Schwartz, G., 535–541
Schwartz, J-C., 110–120, 685–686
Selloum, L., 167–187
Seroogy, K. B., 121–132, 596–597, 636–639
Shafer, R. B., 640–641
Sharkey, K. A., 32–43
Shaw, M. J., 413–416, 640–641
Sheehan, M. J., 642–647
Shillabeer, G., 648–650
Siegel, R. A., 651–653
Silvis, S. E., 640–641
Skirboll, L. R., 152–156, 255–274, 275–282, 403–412
Smith, G. P., 417–423
Stacher, G., 431–436
Steardo, L., 553–561
Steel, D., 678–681
Stengaard-Pedersen, K., 11–23
St-Pierre, S., 198–219
Strohmayer, A. J., 654–655
Strupish, J., 607–608
Studler, J. M., 306–314, 656–659
Suberg, S. N., 660–662, 676–677
Sunkel, D., 53–60
Swanet, E., 470–487
Szabó, G., 293–305

Takahashi, Y., 613–615
Tamminga, C. A., 553–561, 663–665
Tassin, J. P., 306–314
Tatemoto, K., 231–254
Telegdy, G., 293–305
Toni, R., 231–254
Tramu, G., 167–187, 306–314, 568–570, 583–585
Tuong, M. D. T., 110–120
Turner, A. J., 666–668

Urban, L., 385–402

Vaccarino, F. J., 669–670
Vanderhaeghen, J-J., 231–254, 315–333, 334–344, 470–487, 507–517
Vandesande, F., 589–592
van Ree, J. M., 671–673
Van Reeth, O., 334–344
Vargas, F., 110–120
Varro, A., 32–43
Verbanck, P. M. P., 507–517
Verger-Bocquet, M., 167–187
Vigna, S. R., 220–230
Voigt, M. M., 352–360, 674–675
Von Euler, G., 231–254

Wang, R. Y., 352–360, 674–675, 682–684
Watkins, L. R., 660–662, 676–677
Weingartner, H., 542–552
Wennogle, L., 678–681
Westfall, T. C., 674–675
White, F. J., 352–360, 682–684
Willetts, J., 385–402
Williams, J. A., 220–230
Williams, R. G., 32–43
Wimberg, S., 676–677
Wuttke, W., 651–653

Zajac, J. M., 61–75, 593–595
Zetler, G., 448–469, 609–612
Zoli, M., 315–333
Zsigó, J., 293–305
Zuzel, K. A., 110–120, 685–686

Subject Index

Acetylcholine, 507
Accumbens CCK attenuation of brain stimulation reward, in ventral tegmental area, 669–670
Achaeta, 177–178
ACTH, 77
  CCK regulation of release of, 152–155
  releasing hormone, CCK co-existence with, 152–156
Adenylate cyclase, dopamine receptors coupled to, 312
Amacrine cells
  perikarya and, 161–163
  in retina, 129
Amino acids, sequences of, 613
Aminopeptidase, 66
Amphetamine, 476–478
Amygdala, CCK receptor sites in, 213
Amygdaloid complex, 134
Analgesia systems
  morphine, proglumide effects on, 630–632
  opiate antagonistic function of CCK in, 437–447
Annelida, 171–178
Anterior 6-OHDA lesions, 234–237
Anticonvulsant effects, 454–456
Antinociception, 457–459
Antipsychotic action
  of CCK, neurolepsy and, 671–673
  of ceruletide, in schizophrenia, 518–534
Antisera, sequence-specific, CCK studies and, 24–31
Antistereotypic effects, 452–454
Apomorphine, 451–452, 453, 475–476
  motor activity decreased by, 671
Autoradiographic localization, of CCK receptors in brain, 624–626
Autoradiography, CCK receptor, 188–189

Basal ganglia
  in Huntington's disease, CCK content, 488–494
  radioligand concentrations in, 213
Benzodiazepine receptor agonists, antagonism of CCK-induced activation by, 575–580
Benzodiazepines, binding sites for, 575
Binding properties of CCK, 593–595
  in brain, 61–75
Biosynthesis of CCK, in neuronal tissue, 76–86
Bombesin, 2
Brain
  autoradiographic localization of CCK receptors in, 624–626
  CCK and dopamine interaction in, 293–305
  CCK content changes after subchronic treatment in, in rats, 601–603
  CCK immunoreactivity distribution in, 656–659
  CCK in, 11–23
    conformation, enzymatic degradation, potency and binding properties of, 61–75
    in different species using antisera, 24–31
    neurochemistry of, 44–52
    receptors for, 220–230
  CCK-mediated behavioral effects on, 424–425
  CCK receptors in
    affinity and specificity of, 222–224
    covalent cross-linking of, 225–226
    regional distribution of, 224–225
  cortex
    CCK concentrations in, 6
    CCK innervation of, 636–639
    CCK recognition sites in, 678–681
    in rats, 133–143
  cytoplasmic fraction of, CCK hydrolysis by, 87
  discrete regions of, sex and estrous cycle and, 651–653
  immunoreactive cells of, 178–179
  mammalian, CCK receptors in, 198–219
  medulla, CCK cell bodies in, 129
  membranes of, CCK binding to, 221–222
  neuronal pathways of, in rats, 121–132, 133–143
  neutralization of endogenous CCK in, 426
  sensory pathway in, tracing of, 586–588
  species and size selection of, in CCK brain studies, 12
  striatum, in rats, 133–143
  tissue, CCK potency in, 61–75
  ventral tegmental area of, stimulation reward in, 669–670
  See also specific parts of the brain
Brainstem auditory system, CCK-like immunoreactivity distribution in, 563–565

Caerulein, antinociceptive action of, naloxone potentiation of, 642–647
Cardiovascular modification, CCK-induced, 381–382

Catalepsy, 451
Cats, visual cortex of, CCK-containing neuron distribution in, 589–592
CCK
  analogues of, binding of, 70–72
  anatomical studies of, in neurons and pathways involved in neuroendocrine regulation, 144–151
  behavioral effects of, in neofrontal-decorticated rats, 616–620
  biosynthesis of, in neural tissue, 76–86
  brain, *see* Brain—CCK in
    co-existence with ACTH-releasing hormone of, 152–156
  comparative distribution of, 1–8
  conformational analysis and structural activity relationship of, 598–600
  conformational analysis of, by fluorescence transfer energy, 63–65
  degradation processes and binding properties of, 593–595
  dopamine interactions with
    in nucleus accumbens, 352–360
    in rats, 315–333
  elution of, and ion exchange chromatography, 16
  gastrin co-existence with
    in hypophysis and hypothalamus, 334–344
    in nervous system, 32–43
  human gene of, molecular cloning of, 613–615
  identification of, in tissue extracts, 14
  in vivo sulfation of, 293–305
  molecular, *see* Molecular forms of CCK
  neurochemistry of, in brain, pituitary, and cerebrospinal fluid, 44–52
  psychopharmacological profile of, using self-stimulation and drug discrimination paradigms, 470–487
  pyloric receptor of, 621–623
  receptors for
    anatomical and physiological studies of, 188–197
    autoradiographic localization of, 624–626
    effects on feeding and gastric emptying in neonatal rat of, 627–629
    in mammalian brain, 198–219
  satiety effects of, 417–423
    in lean and obese men, 431–436
  species differences in response to, 413–416
  specific assay for, 566–567
  uniqueness of, 1–8
CCK cDNA, rat, isolation and sequence of, 53–55
CCK-like peptides, *see* Peptides—CCK-like
Central nervous system
  CCK and dopamine receptor interactions in, in rats, 315–333
  CCK in
    and control of feeding, 424–430
    enzymatic degradation of, 87–98
  proglumide as CCK antagonist in, 345–351
Cerebral CCK, *see* Brain—CCK in
Cerebral cortex, *see* Brain—cortex
Cerebral glucose, CCK effect on utilization of, 663–665
Cerebral striatum, *see* Brain—striatum
Cerebrospinal fluid
  CCK in, neurochemistry of, 44–52
  in schizophrenia and Parkinson's disease, CCK levels reduced in, 507–517
Ceruletide
  antipsychotic effects of, in schizophrenia, 518–534
  food intake suppressed by, 434
  nociceptive activity and, in rat spinal cord, 609–612
  satiety effects of, in lean and obese men, 431–436
  schizophrenia effects of, 507–517
  schizophrenia treatment using, 511–514, 543, 545
Chlordiazepoxide, 576
Chlorpromazine, 479
Cholecystokinin, *see* CCK
Cloning of human CCK gene, 613–615
Cobalt, 367–371
Colchicine, 589
COOH-terminal amino acids, CCK relationship to, 24–31
Corpora cardiaca, immunoreactive material in, 179
Cortical regions, *see* Brain—cortex
Corticotropin, *see* ACTH
Covalent cross-linking of brain receptors, 220–230
Cultured spinal neurons, CCK and, 403–412

DA, *see* Dopamine
Degradation processes
  of CCK, 68–69, 593–595
  of enzymes, 61–75
Depolarization, CCK-evoked, 364–367
Dentate gyrus, neurons of, CCK as excitant of, 361–374
Desulfation
  of CCK, in brain, 110–120
  neuronal electrical activity reduced by, 301
Diazepam, 576
DNA, cloned, probe using, 613
Dopamine
  brain CCK interaction with, 293–305

Dopamine (cont.)
CCK co-localization and, 6
CCK effect on release of, in nucleus accumbens, 674–675
CCK interactions with, 353–358
in nucleus accumbens, 352–360
in rats, 315–333
endogenous, depolarization-evoked release of, 607–608
midbrain cell activity of, CCK effect on, 346–347
nerve terminals of, CCK effects on, 237–250
neuron system of
CCK neuron system interaction with, 231–254
CCK treatment on, 682–684
nucleus accumbens behavior mediated by, CCK potentiation and, 283–292
substantia nigra interaction with, 275–282
synaptically released endogenous, CCK secretion increased by, 62
Dorso-medial medulla, 41
Drug discrimination paradigm, psychopharmacological profile of CCK using, 470–487

Eating
disorders in, CCK treatment for, 418–419
electrically elicited, CCK and proglumide effects on, 633–635
Echinoderms, 179
Electrically elicited eating, CCK and proglumide effects on, 633–635
Endopeptidase 24.11, 92–95
CCK metabolism by, 666–668
Energy balance systems, opiate antagonistic function of CCK in, 437–447
Enkephalinase, 92–96
assessment of, in CCK inactivation, 685–686
CCK degradation by, 68
Enzymes, degradation of, 61–75
in central nervous system, 87–98
Estrous cycle, CCK in discrete brain regions as function of, 651–653
Evolutionary aspects of brain CCK receptors, 220–230
Exploration, CCK actions on, sensory pathway tracing and, 586–588

Feeding
CCK actions on
in normal and vagotomized men, 640–641
sensory pathway tracing and, 586–588
control of, central nervous system CCK and, 424–430
increased, proglumide-caused, 648–650
Fluorescence transfer energy, CCK conformational analysis by, 63–65
Flurazepam, 576
Footshock-induced analgesias, 438
Forebrain projections, from midbrain CCK-containing neurons, in rats, 596–597
Fractionation techniques, 14
Frogs, retina of, CCK metabolism in, 158–159

Gastric emptying
CCK action on, in normal and vagotomized man, 640–641
CCK inhibition of, 621, 628
Gastrins
CCK co-existence with
in hypophysis and hypothalamus, 334–344
in nervous system, 32–43
identification of, in tissue extracts, 14
neuronal, CCK relationship to, 11–24
in pancreas, 39
in pituitary gland, 37, 46–50
in vagus, 39
Gel chromatography, CCK elution and, 16
Genes
expression of, modulation of, 53–60
human CCK, cloning of, 613–615
rat CCK, 58–59
Glucose, cerebral, CCK effect on utilization of, 663–665
Glutamate, membrane resistance and, 363

Haloperidol, 479–482
treatment with, 322–323
Heterogeneity of CCK peptides, 267–270
Hippocampus, microiontophoretic studies in, 575–580
Hirudinea, 177–178
Homeostasis, 315
Huntington's disease, basal ganglia in, CCK content in, 488–494
Hydrophobic proteins, CCK interaction with, 65
Hypophysis, CCK and gastrin co-existence in, 334–344
Hypothalamic catecholaminergic mechanisms, CCK effects on, 246
Hypothalamo-hypophyseal system
anatomical aspects of CCK in, 335–339
biochemical aspects of CCK in, 334–335
physiological aspects of CCK in, 339–342
Hypothalamus
CCK and gastrin co-existence in, 334–344
CCK cell bodies in, 127
nuclei of, neuropeptides in, 2
Hypothermia, 459

Immunoreactivity
CCK-like
brainstem auditory system distribution of, 563–565
in dorsal horn of rat spinal cord, 583–585
nervous system distribution of, 255–274
in rat nucleus accumbens, 568–570
distribution of, in brain, 656–659
gastrin-like, 9
Ingestion, CCK effect on, 627–628
Insects, 178–180
Intestines
CCK as regulatory peptide in, 24
vasoactive peptides in, behavioral effects of, 616–620
Intracerebral transplants, *see* Transplants—intracerebral
Ion exchange chromatography, CCK elution and, 16
Invertebrates, nervous system of, CCK in, 167–187

Lesions
anterior 6-OHDA, 234
CCK responsivity effects on, 278–279
effects of, 135–142
substantia nigra-dopamine relationship and, 276–277
Ligands, tritiated, 593–595
Limbic lobe, in schizophrenia, CCK levels reduced in, 495–506
Limbic regions, CCK concentrations in, 6
Limbic system, CCK-positive cells in, 126
Locomotor activity, central vs. peripheral CCK on, in rats, 604–606
Lorazepam, 576

Mammals, brain of, *see* Brain—mammalian
Medulla, CCK cell bodies in, 129
Medullary catecholamine neurons, 265
Men, lean and obese, CCK satiety effects in, 431–436
Mesencephalic dopamine neurons, CCK-like immunoreactivity in, 257–263
Mesotelencephalic pathways, CCK-immunoreactive, mapping of, 232–237
Methionine, oxidation of, 571–572
Methylphenidate, 453
Microiontophoretic studies in rat hippocampus, 575–580
Midbrain
CCK cell bodies in, 127
CCK-containing neurons in, forebrain projections from, 596–597
dopamine neurons in, CCK treatment on, 682–684
Molecular cloning of human CCK gene, 613–615
Molecular forms of CCK
in brain, 11–23
in nervous system, 9–10
Mollusks, 179
Morphine
analgesia and tolerance of, proglumide effects on, 630–632
nociceptive activity and, in rat spinal cord, 609–612
reversal of tolerance to, by proglumide, 676–677
spinal transmission inhibition induced by, proglumide, 660–662
See also Opiates

Naloxone
caerulein antinociceptive action potentiation of, 642–647
CCK antagonism by, 573–574
motor activity suppression and, 573
Nervous system
CCK and gastrin co-existence in, 32–43
CCK-like reactivity distribution in, 255–274
invertebrate, CCK in, 167–187
molecular forms of CCK in, 9–10
protochordate, CCK in, 167–187
See also Central nervous system; Peripheral nervous system
Neural lobe of pituitary gland, CCK in, 144
Neural tissue, CCK in, biosynthesis of, 76–86
Neuroendocrine system
function of, CCK effects on, 246–249
regulation of, neurons and pathways involved in, 144–151
studies of, with CCK peptides, 535–541
Neurolepsy, CCK antipsychotic action and, 671–673
Neuroleptics, CCK content changes after subchronic treatment with, 601–603
Neuromodulator, CCK as, 295–297
Neuronal cholecystokinin, *see* CCK
Neurons
CCK and dopamine interacting, 231–254
CCK-containing
cat visual cortex distribution of, 589–592
electrophysiological studies of, 191–195
cultured spinal, CCK and, 403–412
of dentate gyrus, CCK as excitant of, 361–374
forebrain projections from midbrain CCK-containing, in rats, 596–597
medullary catecholamine, 265
mesencephalic dopamine, CCK-like immunoreactivity in, 257–263

Neurons (cont.)
midbrain dopamine, CCK treatment on, 682–684
in neuroendocrine regulation, 144–151
pathways of, in rat brain, 121–132, 133–143
rat spinal dorsal horn, CCK effect on, 385–402
See also Brain; Pathways
Neurophysin, 76–77
Neuropsychiatric disease, CCK-mediated synaptic function and treatment of, 553–561
Neurotensin, 2
Neurotransmitter, CCK as, 80–81
NMR spectroscopy, CCK conformational analysis by, 63–65
Nociceptive activity in rat spinal cord, 609–612
Noradrenaline, 507
Nucleus accumbens, 61
CCK and dopamine interactions in, 352–360
CCK-immunoreactive fiber innervation of, 308–310
CCK-like immunoreactivity in, 568–570
dopamine-mediated behaviors in, CCK potentiation of, 283–292
dopamine neuron innervation of, 307–308
dopamine release in, CCK effects on, 674–675
dopaminergic agent effects on, 311–312
as mesolimbic projection terminal region, 290
neuron innervating of, 306–314
tyrosine hydroxylase and, 103–106
Nucleus tractus solitarius, CCK effects in, 375–384

Obesity
behavioral satiety deficit and, CCK alteration of, 654–655
CCK satiety effects and, 431–436
Olfactory system, CCK-positive cells in, 126
Oligochaeta, 177
Opiates
CCK antagonistic function to, in analgesia and energy balance systems, 437–447
CCK involvement with, 62
proglumide enhancement of, 676–677
See also Morphine
Oxidation, CCK, prevention during tissue extraction of, 571–572

Pain regulation, CCK involvement in, 62
Pancreas
enzyme secretions from, CCK and, 640
exocrine, CCK action on, 164
gastrin occurrence in, of ferrets, 39
Paraventricular nucleus, 145–147
medial parvocellular subdivision of, CCK in, 152–156
neuronal systems in, CCK in, 147–150
Parkinson's disease
brain immunoreactivity distribution and, 656–659
cerebrospinal fluid in, CCK levels reduced in, 507–517
Pathways
mesotelencephalic, mapping of, 232–237
in neuroendocrine regulation, 144–151
neuronal, in rat brain, 121–132, 133–143
sensory, tracing of, 586–588
See also Neurons
Peptides
biosynthesis of, 76–78
CCK, neuroendocrine studies with, 535–541
CCK-like
neuropharmacological profile of, 448–469
schizophrenia effects of, 542–552
neuronal, biosynthesis regulation of, 81–82
vasoactive intestinal, behavioral effects of, 616–620
Perikarya, amacrine cells and, 161–163
Peripheral CCK receptor antagonists, competition lack between, 581–582
Peripheral nervous system, CCK concentrations in, 37–41
Pituitary gland
CCK in, neurochemistry of, 44–52
gastrins in, 37, 46–50
neural lobe of, CCK in, 144
Poly(A)RNA, 54–57
Polychaeta, 171
Pons, CCK cell bodies in, 129
Potassium, pulses of, dopamine release increased by, 607
Potency of CCK in brain tissue, 61–75
Preprocholecystokinin
homology of, porcine and rat, 59
rat, structure of, 57–58
Proglumide, 62
CCK antagonism by, 573–574
in central nervous system, 345–351
CCK excitation and, 399
CCK-induced changes in neuronal activity and, 347
effects on electrically elicited eating of, 633–635
effects on morphine analgesia and tolerance of, 630–632

Proglumide (cont.)
increased food intake caused by, 648–650
morphine tolerance reversal and opiate enhancement by, 676–677
spinal transmission by, potentiation of morphine-induced inhibition of, 660–662
Proteins, hydrophobic, CCK interaction with, 65
Protochordates, nervous system of, CCK in, 167–187
Ptosis, 451–452
Pyloric CCK receptor, 621–623

Radioimmunoassays, CCK measurement by, 24–31
Radiolabeling, of CCK, synthesis, 298–299
Radioligands, basal ganglia concentrations of, 213
Rat cortex slices, CCK degradation by, 69–70
Rats
brain of, *see specific topics under* Brain
CCK cDNA in, isolation and sequence of, 53–55
CCK genes in, 58–59
central nervous system of, CCK and dopamine interactions in, 315–333
exploratory behavior in, 464
locomotor activity in, central vs. peripheral CCK on, 604–606
neofrontal-decorticated, CCK and vasoactive intestinal peptide effects on, 616–620
neonatal, gastric CCK receptors effect on feeding and gastric emptying of, 627–629
preprocholecystokinin in
homology of, 59
structure of, 57–58
self-stimulation in, central vs. peripheral CCK on, 604–606
spinal cord, *see* Spinal cord
Rat striatal slices, CCK and dopamine from, depolarization-evoked release of, 607–608
Respiration, CCK injection modification of, 381
Retina
amacrine cells in, 129
CCK localization in, 159–161
of vertebrates, CCK in, 157–166
RNA, 54–57
Rostral telecephalon, 213

Satiety effects
of CCK, 417–423
in lean and obese men, 431–436
CCK alteration of, in obesity, 654–655
CCK as peripheral factor in, 413–414
Schizophrenia
antipsychotic effects of ceruletide in, 518–534
CCK and, 352–353
CCK-like peptide effects in, 542–552
cerebrospinal fluid in, reduced CCK levels in, 507–517
ceruletide effect on, 507–517
ceruletide treatment for, 511–514, 543, 545
limbic lobe in, reduced CCK levels in, 495–506
Self-stimulation
CCK effects on, 459–461
central vs. peripheral CCK on, in rats, 604–606
intracranial, 471–482
paradigm, psychopharmacological profile of CCK using, 470–487
Serum albumin, CCK interaction with, 65
Serotonine, 507
Sexual cycle, CCK in discrete brain regions as function of, 651–653
Species differences in response to CCK, 413–416
Spinal cord
dorsal horn neurons of, CCK effect on, 385–402
dorsal horn of, CCK-like immunoreactivity in, 583–585
nociceptive activity in, 609–612
Structural specificity for CCK-mediated actions, 426
Structure-activity relationships, 461
Subchronic treatment, CCK content changes after, with neuroleptics, 601–603
Subesophageal ganglion, immunoreactive cells of, 179
Substance P, 77
CCK correlations with, 395–397
immunoreactivity in, 267
Substantia nigra, dopamine interaction with, 275–282
Sulfation
of CCK, in brain, 110–120
as dopamine metabolic pathway, 301
in vivo, of CCK octapeptide, 293–305
Synaptic cleft, 62
Synaptic function, CCK-mediated, in neuropsychiatric disease treatment, 553–561
Synaptosomes, CCK degradation by, 68–69

Tachphylaxis, 411
Telencephalic dopaminergic mechanisms, CCK effects on, 238–239
Thalamus, dense labeling in, 213
Thyrotropin-releasing hormone, 2

Tissues
  extracts of
    CCK and gastrin identification in, 14
    CCK oxidation prevention during, 571–572
  neural, transplantation of, 106–107
Transmitter, CCK as, 294–295
Transplants, intracerebral, CCK in, 99–109
Tremors, antagonism of, 456–457
TRH, 77
Tritiated ligands, 593–595
L-Tryptophan, 432
Tyrosine hydroxylase
  host striatum and, 103
  nucleus accumbens and, 103–106
  ventral mesencephalon transplants and, 100–103
Tyrosyl, residue in CCK of, 9

Uniqueness of CCK, 1–8

Vagotomization
  gastric emptying and food intake in, CCK effect on, 640–641
  increased food intake abolished by, 648–650
Vagus nerve
  CCK receptor flow in, 191
  gastrins in, 39
Vasoactive intestinal peptide, behavioral effects of, 616–620
Vasopressin, 75–77
Ventral mesencephalon, transplants from, tyrosine hydroxylases within, 100–103
Vertebrates
  lower, CCK receptors in, 226–228
  retina of, CCK in, 157–166
Visual cortex, CCK-containing neuron distribution in, of cats, 589–592

Weight loss, CCK in, 419

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 448

July 5, 1985

NEURONAL CHOLECYSTOKININ[a]

Editors and Conference Organizers

JEAN-JACQUES VANDERHAEGHEN AND JACQUELINE N. CRAWLEY

CONTENTS

Preface. *By* JEAN-JACQUES VANDERHAEGHEN AND JACQUELINE N. CRAWLEY ... xiii

Comparative Distribution of Cholecystokinin and Other Neuropeptides: Why is This Peptide Different from All Other Peptides? *By* JACQUELINE N. CRAWLEY ... 1

Part I. Neurochemistry

Molecular Forms of Cholecystokinin in the Nervous System. *By* MICHAEL J. BROWNSTEIN and JENS F. REHFELD ... 9

Molecular Forms of Cholecystokinin in the Brain and the Relationship to Neuronal Gastrins. *By* J. F. REHFELD, H. F. HANSEN, P. D. MARLEY, and K. STENGAARD-PEDERSEN ... 11

Studies on Brain Cholecystokinin in Different Species Using Sequence-specific Antisera. *By* J. B. M. J. JANSEN and C. B. H. W. LAMERS ... 24

Cholecystokinin and Gastrin Forms in the Nervous System. *By* G. J. DOCKRAY, H. DESMOND, R. J. GAYTON, A-C. JC ISSON, H. RAYBOULD, K. A. SHARKEY, A. VARRO, and R. G. WILLIAMS ... 32

Neurochemistry of Cholecystokinin in Brain, Pituitary, and Cerebrospinal Fluid. *By* MARGERY C. BEINFELD and ANITA CIARLEGLIO ... 44

Part II. Synthesis and Metabolism

Modulation of Cholecystokinin Gene Expression. *By* ROBERT J. DESCHENES, RANDY S. HAUN, DAN SUNKEL, BERNARD A. ROOS, and JACK E. DIXON ... 53

Studies on the Conformation, Enzymatic Degradation, Pharmacological Potency, and Binding Properties in Brain Tissue of Cholecystokinin-8 and New Related Peptides. *By* B. P. ROQUES, C. DURIEUX, G. GACEL, D. PÉLAPRAT, M. RUIZ-GAYO, J. BELLENEY, E. FELLION, J. M. ZAJAC, M-C. FOURNIÉ-ZALUSKI, V. DAUGÉ, I. MENANT, P. ROSSIGNOL, B. LUX, D. GÉRARD, D. BÉGUÉ, A. SASAKI, and J. L. MORGAT ... 61

The Biosynthesis of Cholecystokinin in Neural Tissue. *By* NILS R. GOLTERMANN ... 76

[a]This volume is the result of a conference on Neuronal Cholecystokinin held by The New York Academy of Sciences and the Fondation Médicale Reine Elisabeth on July 3–6, 1984 in Brussels, Belgium.

Enzymatic Degradation of Cholecystokinin in the Central Nervous System. *By* MONIQUE DESCHODT-LANCKMAN 87

Cholecystokinin in Intracerebral Transplants. *By* M. SCHULTZBERG 99

Sulfation and Desulfation of Cerebral Cholecystokinin. *By* FROYLAN VARGAS, OLIVIER FREROT, MI DAM TRUNG TUONG, KATHERINE ZUZEL, CHRISTIANE ROSE, and JEAN-CHARLES SCHWARTZ 110

Part III. Neuroanatomy

The Distribution and Some Connections of Cholecystokinin Neurons in the Rat Brain. *By* JAMES H. FALLON and KIM B. SEROOGY 121

Studies on Cholecystokinin-containing Neuronal Pathways in Rat Cerebral Cortex and Striatum. *By* D. K. MEYER and Z. PROTOPAPAS 133

Anatomical Studies of Cholecystokinin in Neurons and Pathways Involved in Neuroendocrine Regulation. *By* JOZSEF Z. KISS 144

Cholecystokinin in the Medial Parvocellular Subdivision of the Paraventricular Nucleus: Co-existence with Corticotropin-releasing Hormone. *By* E. MEZEY, T. D. REISINE, L. SKIRBOLL, M. BEINFELD, and J. Z. KISS 152

Cholecystokinin in the Retina of Vertebrates. *By* NEVILLE N. OSBORNE 157

Cholecystokinin in the Nervous Systems of Invertebrates and Protochordates: Immunohistochemical Localization of a Cholecystokinin-8-like Substance in Annelids and Insects. *By* N. DHAINAUT-COURTOIS, G. TRAMU, R. MARCEL, J. MALÉCHA, M. VERGER-BOCQUET, J. C. ANDRIÈS, M. MASSON, L. SELLOUM, G. BELEMTOUGRI, and J. C. BEAUVILLAIN 167

Part IV. Receptors

Integrated Anatomical and Physiological Studies of Neuronal Cholecystokinin Receptors. *By* ROBERT B. INNIS and GEORGE K. AGHAJANIAN 188

Cholecystokinin Receptors in Mammalian Brain: A Comparative Characterization and Visualization. *By* PIERRETTE GAUDREAU, SERGE ST-PIERRE, CANDACE B. PERT, and RÉMI QUIRION 198

Brain Cholecystokinin Receptors: Binding Characteristics, Covalent Cross-linking, and Evolutionary Aspects. *By* JOHN A. WILLIAMS, STEVEN R. VIGNA, CHOITSU SAKAMOTO, and IRA D. GOLDFINE 220

Cholecystokinin Neuron Systems and Their Interactions with the Presynaptic Features of the Dopamine Neuron Systems: A Morphometric and Neurochemical Analysis Involving Studies on the Action of Cholecystokinin-8 and Cholecystokinin-58. *By* K. FUXE, L. F. AGNATI, J-J. VANDERHAEGHEN, K. TATEMOTO, K. ANDERSSON, P. ENEROTH, A. HÄRFSTRAND, G. VON EULER, R. TONI, M. GOLDSTEIN, and V. MUTT 231

Part V. Co-existence

Distribution of Cholecystokinin-like Immunoreactivity in the Nervous System: Co-existence with Classical Neurotransmitters and Other Neuropeptides. *By* T. HÖKFELT, L. SKIRBOLL, B. EVERITT, B. MEISTER, M. BROWNSTEIN, T. JACOBS, A. FADEN, S. KUGA, M. GOLDSTEIN, R. MARKSTEIN, G. DOCKRAY, and J. REHFELD 255

Electrophysiological Studies of the Role of Cholecystokinin in the Substantia Nigra and Its Interactions with Dopamine. *By* L. R. SKIRBOLL and D. W. HOMMER 275

Cholecystokinin Potentiation of Dopamine-mediated Behaviors in the Nucleus Accumbens. *By* JACQUELINE N. CRAWLEY 283

In Vivo Sulfation of Cholecystokinin Octapeptide: Possible Interactions of the Two Forms of Cholecystokinin with Dopamine in the Brain. *By* B. PENKE, G. L. KOVÁCS, J. ZSIGÓ, T. KÁDÁR, G. SZABÓ, K. KOVÁCS, and G. TELEGDY 293

Distinct Properties of Cholecystokinin-8 and Mixed Dopamine-Cholecystokinin-8 Neurons Innervating the Nucleus Accumbens. *By* J. M. STUDLER, M. REIBAUD, G. TRAMU, G. BLANC, J. GLOWINSKI, and J. P. TASSIN 306

Evidence for Cholecystokinin-Dopamine Receptor Interactions in the Central Nervous System of the Adult and Old Rat: Studies on Their Functional Meaning. *By* L. F. AGNATI, K. FUXE, L. GIARDINO, L. CALZA, M. ZOLI, N. BATTISTINI, F. BENFENATI, J-J. VANDERHAEGHEN, D. GUIDOLIN, M. RUGGERI, and M. GOLDSTEIN 315

Co-existence of Cholecystokinin- or Gastrin-like Peptides with Other Peptides in the Hypophysis and the Hypothalamus. *By* J-J. VANDERHAEGHEN, S. GOLDMAN, F. LOTSTRA, O. VAN REETH, C. DESCHEPPER, J. ROSSIER, and S. SCHIFFMANN 334

Part VI. Neurophysiology

Further Studies on the Specificity of Proglumide as a Selective Cholecystokinin Antagonist in the Central Nervous System. *By* B. S. BUNNEY, L. A. CHIODO, and A. S. FREEMAN 345

Interactions of Cholecystokinin and Dopamine in the Nucleus Accumbens. *By* REX Y. WANG, FRANCIS J. WHITE, and MARK M. VOIGT 352

Cholecystokinin as a Potent Excitant of Neurons of the Dentate Gyrus of Rats. *By* PENNY A. BROOKS and JOHN S. KELLY 361

The Effects of Cholecystokinin-8 in the Nucleus Tractus Solitarius. *By* M. DENAVIT-SAUBIÉ, M. A. HURLÉ, M. P. MORIN-SURUN, A. S. FOUTZ, and J. CHAMPAGNAT 375

Actions of Cholecystokinin Octapeptide on Rat Spinal Dorsal Horn Neurons. *By* J. WILLETTS, L. URBAN, K. MURASE, and M. RANDIĆ 385

Cholecystokinin and Cultured Spinal Neurons: Immunohistochemistry, Receptor Binding, and Neurophysiology. *By* M. A. ROGAWSKI, M. C. BEINFELD, S. E. HAYS, T. HÖKFELT, and L. R. SKIRBOLL 403

Part VII. Behavior

Species Differences in the Response to Cholecystokinin. *By* JOHN E. MORLEY, ALLEN S. LEVINE, TIMOTHY J. BARTNESS, STEVEN E. NIZIELSKI, MICHAEL J. SHAW, and JOHN J. HUGHES 413

The Satiety Effect of Cholecystokinin: Recent Progress and Current Problems. *By* G. P. SMITH and J. GIBBS 417

Central Nervous System Cholecystokinin and the Control of Feeding. *By* CLIFTON A. BAILE and MARY ANNE DELLA-FERA 424

Satiety Effects of Cholecystokinin and Ceruletide in Lean and Obese Man. *By* GEORG STACHER 431

Opiate Antagonistic Function of Cholecystokinin in Analgesia and Energy Balance Systems. *By* PATRICIA L. FARIS 437

Neuropharmacological Profile of Cholecystokinin-like Peptides. *By* GERHARD ZETLER 448

Psychopharmacological Profile of Cholecystokinin Using the Self-Stimulation and the Drug Discrimination Paradigms. *By* P. DE WITTE, E. SWANET, M. GEWISS, S. GOLDMAN, B. ROQUES, and J-J. VANDERHAEGHEN 470

Part VIII. Clinical Significance

Cholecystokinin Content in the Basal Ganglia in Huntington's Disease: The Expression of Cholecystokinin Immunoreactivity in Striatal Grafts to Ibotenic Acid-lesioned Rat Striatum. *By* P. C. EMSON, D. DAWBARN, M. N. ROSSOR, J. F. REHFELD, P. BRUNDIN, O. ISACSON, and A. BJÖRKLUND 488

Reduced Cholecystokinin Levels in the Limbic Lobe in Schizophrenia: A Marker for Pathology Underlying the Defect State? *By* I. N. FERRIER, T. J. CROW, S. M. FARMERY, G. W. ROBERTS, F. OWEN, T. E. ADRIAN, and S. R. BLOOM 495

Reduced Cholecystokinin Levels in Cerebrospinal Fluid of Parkinsonian and Schizophrenic Patients: Effect of Ceruletide in Schizophrenia. *By* F. LOTSTRA, P. M. P. VERBANCK, C. GILLES, J. MENDLEWICZ, and J-J. VANDERHAEGHEN 507

Antipsychotic Effects of Ceruletide in Chronic Schizophrenia: An Appraisal of the Long-term, Intermittent Medication of Ceruletide in Chronic Schizophrenia. *By* TAKASHI MOROJI, KOICHI ITOH, and KOZO ITOH 518

Clinical and Neuroendocrine Studies with Cholecystokinin Peptides. *By* N. P. V. NAIR, D. BLOOM, S. LAL, G. DEBONNEL, G. SCHWARTZ, and S. MOSTICYAN 535

The Effects of Cholecystokinin-like Peptides in Schizophrenics and Normal Human Subjects. *By* DANIEL W. HOMMER, DAVID PICKAR, JACQUELINE N. CRAWLEY, HERBERT WEINGARTNER, and STEVEN M. PAUL 542

Cholecystokinin-mediated Synaptic Function and the Treatment of Neuropsychiatric Disease. *By* T. N. CHASE, P. BARONE, G. BRUNO, S. L. COHEN, J. JUNCOS, M. KNIGHT, S. RUGGERI, L. STEARDO, and C. A. TAMMINGA 553

Poster Papers

Distribution of Cholecystokinin-like Immunoreactivity in the Brainstem Auditory System. *By* J. C. ADAMS and E. MUGNAINI 563

A New Specific Assay for Cholecystokinin Octapeptide. *By* T. E. ADRIAN, A. J. BACARESE-HAMILTON, and S. R. BLOOM 566

Cholecystokinin-like Immunoreactivity in the Rat Nucleus Accumbens: An Ultrastructural Study. *By* H. BAALI-CHERIF, M. ARLUISON, and G. TRAMU 568

Prevention of Cholecystokinin Oxidation During Tissue Extraction: A Major Problem Solved. *By* A. J. BACARESE-HAMILTON, T. E. ADRIAN, and S. R. BLOOM 571

Antagonism of Cholecystokinin by Naloxone and Proglumide in Mice. *By* B. S. BARBAZ, W. L. AUTRY, F. G. AMBROSE, R. GERBER, and J. M. LIEBMAN ... 573

Antagonism of Cholecystokinin-induced Activation by Benzodiazepine Receptor Agonists: Microiontophoretic Studies in the Rat Hippocampus. *By* JACQUES BRADWEJN and CLAUDE DE MONTIGNY 575

Lack of Competition between Two Reputed Peripheral Cholecystokinin Receptor Antagonists for Central Cholecystokinin Binding Sites. *By* COLIN R. CLARK, PETER DAUM, and JOHN HUGHES 581

Cholecystokinin-like Immunoreactivity in the Dorsal Horn of the Rat Spinal Cord. *By* M. CONRATH-VERRIER, M. DIETL, and G. TRAMU 583

Tracing the Sensory Pathway from the Gut to Brain Regions Mediating the Actions of Cholecystokinin on Feeding and Exploration. *By* JACQUELINE N. CRAWLEY and JOZSEF Z. KISS 586

Distribution of Cholecystokinin-containing Neurons in Cat Visual Cortex. *By* H. DEMEULEMEESTER, F. VANDESANDE, and G. A. ORBAN 589

Degradation Processes and Binding Properties of Cholecystokinin and Related Compounds: Studies Using a New Tritiated Ligand. *By* CHRISTIANE DURIEUX, DIDIER PÉLAPRAT, JEAN MARIE ZAJAC, MARIE-CLAUDE FOURNIÉ-ZALUSKI, GILLES GACEL, and BERNARD P. ROQUES 593

Forebrain Projections from Midbrain Cholecystokinin-containing Neurons in the Rat. *By* JAMES H. FALLON and KIM B. SEROOGY 596

Conformational Analysis and Structural Activity Relationships of Cholecystokinin Peptides. *By* M-C. FOURNIÉ-ZALUSKI, J. BELLENEY, C. DURIEUX, G. GACEL, B. P. ROQUES, D. BÉGUÉ, I. MENANT, B. LUX, and D. GÉRARD 598

Changes in Cholecystokinin Content in Rat Brain after Subchronic Treatment with Neuroleptics. *By* PETER FREY 601

Central versus Peripheral Cholecystokinin Octapeptide on Self-Stimulation and Locomotor Activity in the Rat. *By* A. J. GOWER and C. L. E. BROEKKAMP. 604

Depolarization-evoked Release of Endogenous Dopamine and Cholecystokinin from Rat Striatal Slices. *By* J. B. HUTCHISON, S. R. NAHORSKI, and J. STRUPISH 607

Effects on Ascending Nociceptive Activity in the Rat Spinal Cord Produced by Cholecystokinin Octapeptide, Ceruletide, and Morphine Injected into the Periaqueductal Gray Matter. *By* ILMAR JURNA and GERHARD ZETLER 609

Molecular Cloning of the Human Cholecystokinin Gene. *By* KIKUYA KATO, YOOSUKE TAKAHASHI, and KENICHI MATSUBARA 613

Behavioral Effects of Cholecystokinin and Vasoactive Intestinal Peptide in Neofrontal-decorticated Rats. *By* GORO KATSUURA and SHINJI ITOH 616

The Pyloric Cholecystokinin Receptor: A Site of Mediation for Satiety? *By* TIMOTHY H. MORAN, PAUL H. ROBINSON, and PAUL R. MCHUGH 621

Autoradiographic Localization of Cholecystokinin Receptors in Human Brain. *By* RÉMI QUIRION, CATHERINE CSONKA, PIERRE ETIENNE, N. P. V. NAIR, YVES ROBITAILLE, and PIERRETTE GAUDREAU 624

Gastric Cholecystokinin Receptors and the Effect of Cholecystokinin on Feeding and Gastric Emptying in the Neonatal Rat. *By* PAUL H. ROBINSON, TIMOTHY H. MORAN, and PAUL R. MCHUGH 627

Effects of Proglumide on Morphine Analgesia and Tolerance. *By* LUCIO C. ROVATI, PAOLA SACERDOTE, and ALBERTO E. PANERAI 630

The Effects of Cholecystokinin Octapeptide and Proglumide on Electrically Elicited Eating. *By* LINDA H. SCHNEIDER, JOEL M. KAPLAN, SAMUEL M. FELDMAN, EDGAR E. COONS, and RANDALL B. MURPHY 633

Cholecystokinin Innervation of Rat Cerebral Cortex. *By* KIM B. SEROOGY and JAMES H. FALLON 636

Cholecystokinin Octapeptide Action on Gastric Emptying and Food Intake in Normal and Vagotomized Man. *By* M. J. SHAW, J. J. HUGHES, J. E. MORLEY, A. S. LEVINE, S. E. SILVIS, and R. B. SHAFER 640

Naloxone Potentiation of the Antinociceptive Action of Caerulein. *By* M. J. SHEEHAN and J. DE BELLEROCHE 642

Increased Food Intake in the Rat Caused by Proglumide, the Cholecystokinin Antagonist: An Effect Abolished by Vagotomy. *By* G. SHILLABEER and J. S. DAVISON 648

Cholecystokinin in Discrete Rat Brain Regions as a Function of Sex and Estrous Cycle. *By* R. A. SIEGEL, M. FRANKFURT, U. PAHNKE, and W. WUTTKE 651

The Effect of Cholecystokinin on a Behavioral Satiety Deficit in Obese Mice. *By* ALAN J. STROHMAYER 654

Cholecystokinin Octapeptide Immunoreactivity Distribution in Human Brain: Modifications in Parkinsonian Patients. *By* J. M. STUDLER and F. JAVOY-AGID 656

The Potentiation of Morphine-induced Inhibition of Spinal Transmission by Proglumide, a Putative Cholecystokinin Antagonist. *By* S. N. SUBERG, E. S. CULHANE, E. CARSTENS, and L. R. WATKINS 660

Cholecystokinin Octapeptide's Effect on Local Cerebral Glucose Utilization in the Laboratory Rat. *By* C. A. TAMMINGA, G. LUCIGNANI, L. J. PORRINO, and T. N. CHASE 663

Metabolism of Cholecystokinin by Endopeptidase-24.11. *By* ANTHONY J. TURNER, REBECCA MATSAS, and A. JOHN KENNY 666

Accumbens Cholecystokinin Attenuation of Brain Stimulation Reward in the Ventral Tegmental Area. *By* F. J. VACCARINO and G. F. KOOB 669

Neuroleptic-like Activity and Antipsychotic Action of Cholecystokinin-related Peptides. *By* JAN M. VAN REE and DAVID DE WIED 671

Effects of Cholecystokinin on Dopamine Release in the Nucleus Accumbens. *By* MARK M. VOIGT, REX Y. WANG, and THOMAS C. WESTFALL 674

The Enhancement of Opiate Analgesia and the Possible Reversal of Morphine Tolerance by Proglumide. *By* L. R. WATKINS, I. B. KINSCHECK, G. ROSENQUIST, J. MILLER, S. WIMBERG, H. FRENK, E. KAUFMAN, R. COGHILL, S. N. SUBERG, and D. J. MAYER 676

Characterization of Cholecystokinin Recognition Sites in Mouse Cerebral Cortex Using a Radiolabeled Octapeptide. *By* LAWRENCE WENNOGLE, DOUGLAS STEEL, and BARBARA PETRACK 678

Effects of Chronic Treatment with Cholecystokinin on Midbrain Dopamine Neurons. *By* FRANCIS J. WHITE and REX Y. WANG 682

Assessment of the Role of "Enkephalinase" in Cholecystokinin Inactivation. *By* KATHERINE A. ZUZEL, CHRISTIANE ROSE, and JEAN-CHARLES SCHWARTZ 685

Index of Contributors 687

Subject Index 691

Financial assistance was received from:

ABBOTT LABORATORIES
ANALIS S.A., LABORATORY INSTRUMENTS
CIBA-GEIGY CORPORATION/PHARMACEUTICALS DIVISION
E.I. DU PONT DE NEMOURS & COMPANY/CENTRAL RESEARCH AND DEVELOPMENT DEPARTMENT/PHARMACEUTICALS, BIOMEDICAL PRODUCTS DEPARTMENT
FARMITALIA CARLO ERBA, S.A.
FIDIA RESEARCH LABORATORIES
FONDATION MÉDICALE REINE ELISABETH
FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE BELGE
GROUPE DE RECHERCHE SERVIER
LABORATOIRE FOURNIER
LABORATOIRE RHÔNE-POLENC SANTÉ
LABORATOIRE ROUSSEL UCLAF
LOTERIE NATIONALE BELGE
MERCK SHARP & DOHME RESEARCH LABORATORIES
MICRO BELGIUM APPLICATION
MILLIPORE, S.A./WATERS PRODUCT DIVISION–BELGIUM
MINISTERE DE L'EDUCATION NATIONALE ET DE LA CULTURE FRANÇAISE BELGE
NATIONAL INSTITUTE OF MENTAL HEALTH–NIH, USA
NATIONAL SCIENCE FOUNDATION, USA
A.H. ROBINS COMPANY/RESEARCH AND DEVELOPMENT DIVISION
ROCHE–BELGIQUE
SANDOZ, LTD.
SEARLE RESEARCH AND DEVELOPMENT/DIVISION OF G.D. SEARLE & COMPANY
SHIONOGI RESEARCH LABORATORIES/SHIONOGI & COMPANY, LTD.
STUART PHARMACEUTICALS/DIVISION OF ICI AMERICAS, INC.
E.R. SQUIBB & SONS, INC.
UNION CHIMIQUE BELGE/BIOPRODUCTS
UNITED STATES AIR FORCE OFFICE OF SCIENTIFIC RESEARCH
THE UPJOHN COMPANY–BELGIUM
VAN HOPPLYNUS OPTIQUE
WARNER LAMBERT COMPANY/PHARMACEUTICAL RESEARCH DIVISION

The New York Academy of Sciences believes that it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the authors of the papers that make up this *Annal* are their own and not necessarily those of the Academy. The Academy has no intent to influence legislation by providing such forums.